Curated from social media posts and threads
Trump Administration Reclassifies State Medical Cannabis as Less Dangerous
Acting AG signs historic order moving state-licensed medical marijuana down from Schedule I, marking major policy shift after decades of federal prohibition. Read on AP News →
Akanda (AKAN) Posts Stunning 1,700% April Rally on Rescheduling Optimism
Small-cap medical cannabis stock surges as traders rotate into stocks with exposure to future regulatory tailwinds. View on StockTwits →
Ayr Wellness Leads Sector Rally with +30.7%
Multi-state operator leads Thursday gains; however, sector divergence continues. Check Stocks Tracker →
TerrAscend Positions for Growth Post-Rescheduling
Leading medical cannabis operator plans to leverage federal rescheduling to drive growth and shape policy. Read on MJBizDaily →
Cannabis-Based Drug Companies Eye IPOs & Private Funding
Pharmaceutical firms developing cannabis medicines say US moves to ease restrictions unlock IPO access and private capital. Read on Reuters →
House Passes 2026 Farm Bill: Hemp Provisions Updated
Legislation tightens intoxicating hemp rules while loosening regulatory burdens for industrial hemp producers. Full Details →
DEA Schedule III Registration Creates Confusion
Operators express distrust of federal registration framework. Regulatory clarity remains pending as state-licensed businesses navigate compliance. Analysis →
Cannabis Use Among Americans 65+ Up 46% (2021-2023)
New study shows rapid adoption among seniors, reflecting growing acceptance and expanding addressable market. Read on CBS News →
Trump Rescheduling Creates Mixed Signals
Medical cannabis reclassified while broader recreational legalization status remains unclear. Analysis on The Guardian →
Psychedelic & Cannabis Reforms Reshape Mental Health Markets
ATAI Life Sciences and others positioned to benefit from accelerated regulatory environment for novel formulations. Read on Investing News →
Published: Friday, May 1, 2026 | 1:05 PM ET | Curated by Sheeba